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A B S T R A C T
Objective: We investigated whether T. gondii seropositivity is associated with 12-month depressive, anxiety and
alcohol use disorders and current depressive symptoms and whether inflammation, measured by C-reactive
protein (CRP) level, explains these associations.
Method: Health 2000 study (BRIF8901), conducted in years 2000–2001, is based on a nationally representative
sample of Finns aged 30 and above, with 7112 participants and 88.6% response rate. DSM-IV depressive, anxiety
and alcohol use disorders were assessed with the Composite International Diagnostic Interview and depressive
symptoms with the Beck Depressive Inventory (BDI-21). We used logistic regression to investigate the associa-
tion of T. gondii seropositivity with mental disorders and linear regression with BDI-21 scores.
Results: T. gondii seroprevalence was significantly associated with 12-month generalized anxiety disorder but not
with other anxiety, depressive or alcohol use disorders. T. gondii seropositivity was associated with higher BDI-
21 scores (beta 0.56, 95% CI 0.12–1.00, P = 0.013) and with having a comorbid depressive and anxiety disorder
(OR 1.86, 95% CI 1.16–2.97, P = 0.010). Higher CRP levels were associated with these outcomes and with T.
gondii seropositivity, but adjusting for CRP did not change the effect of T. gondii seropositivity.
Limitations: Cross-sectional study design with no information on the timing of T. gondii infection.
Conclusion: T. gondii seropositivity is associated with generalized anxiety disorder, depressive symptoms and
comorbid depressive and anxiety disorders, which is not mediated by inflammation.
1. Introduction
Toxoplasma gondii (T. gondii) is an intracellular parasite that usually
causes an inapparent primary infection but remains then latent in the
body and may become reactivated later in life (Saadatnia and Golkar,
2012). The most common sources of infection are ingestion of food or
water that is contaminated with oocysts shed by cats or by eating un-
dercooked or raw meat containing tissue cysts (Montoya and Liesenfeld,
2004; Saadatnia and Golkar, 2012).
T. gondii seropositivity has been associated with several mental
disorders (Sutterland et al., 2015). A recent meta-analysis investigated
its association with schizophrenia, bipolar disorder, major depressive
disorder (MDD) and addiction (mainly opioid dependence), and found
significant association with schizophrenia, bipolar disorder and addic-
tion but not with MDD (Sutterland et al., 2015). In addition, previous
reports have associated T. gondii seropositivity with depressive and
anxiety symptoms (Groër et al., 2011; Duffy et al., 2015), generalized
anxiety disorder (GAD) (Markovitz et al., 2015), obsessive-compulsive
disorder (OCD) (Miman et al., 2010), suicidality (Zhang et al., 2012),
mixed anxiety and depressive disorder (Alvarado-Esquivel et al., 2016)
and aggression and impulsivity (Cook et al., 2015). However, negative
findings have also been published (Gale et al., 2014; Sugden et al.,
2016).
The prevalence of T. gondii seropositivity varies markedly by region,
age, and ethnic group (Saadatnia and Golkar, 2012; Sutterland et al.,
2015), complicating comparisons between studies. Finland is an eth-
nically homogeneous Nordic country with relatively low T. gondii ser-
oprevalence (von Hertzen et al., 2006). Here, we investigated the as-
sociation of T. gondii seroprevalence and serointensity with mental
health in a large, population-based representative sample of adult
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Finns.
We investigated the association of T. gondii seropositivity and ser-
ointensity with 12-month DSM-IV anxiety, depressive and alcohol use
disorders as well as current depressive symptoms, adjusting for other
factors associated with these disorders or with T. gondii seroprevalence.
Furthermore, we investigated whether the effect of T. gondii ser-
opositivity/serointensity could be explained by inflammation, which
was measured by sensitive C-reactive protein (CRP) level.
2. Materials and methods
2.1. Participants
The Finnish Health 2000 Survey was based on a nationally re-
presentative sample of 8028 persons aged 30 years or over from Finland
(Aromaa and Koskinen, 2004). A two-stage stratified cluster sampling
design was used to ensure that the sample was representative of the
whole country. The sampling frame comprised adults aged 30 years and
over living in mainland Finland. The field work took place between
September 2000 and June 2001, and consisted of a home interview and
a health examination at the local health center, or a condensed inter-
view and health examination of non-respondents at home. In addition,
several questionnaires were used to assess symptoms, lifestyle, and
exposures related to different health problems. Descriptive data on the
participants is presented in Table 1. Plasma samples were collected as a
part of the health examination. Stored samples were available from
6250 participants for the current study.
The Health 2000 survey was approved by the Ethical Committee of
THL and the Coordinating Ethics Committee at the Hospital District of
Helsinki and Uusimaa. Written informed consent was received from
each participant.
2.2. Mental health assessment
Mental disorders were assessed using the Munich-Composite
International Diagnostic Interview or M-CIDI (Wittchen et al., 1998),
using the sections on mood, anxiety and substance use disorders. These
sections covered eight DSM-IV diagnoses: MDD and dysthymia, com-
bined as depressive disorders; panic disorder with or without agor-
aphobia, agoraphobia without panic disorder, social phobia and GAD,
combined as anxiety disorders, and alcohol abuse and dependence,
combined as alcohol use disorders (Pirkola et al., 2005). The presence
of symptoms within the past 12 months (12-month prevalences) were
assessed. Of the total sample, 6005 (74.8%) completed the CIDI inter-
view, and blood samples were available for 5917 (98.5%) of them.
In addition, current depressive symptoms were enquired about
using the 21-item version of the Beck Depression Inventory (BDI-21)
(Beck et al., 1961).
2.3. Sociodemographic variables
We used the following sociodemographic variables in the analysis:
age, sex, education and place and region of residence.
Information on general education and on higher and vocational
education was combined into a variable describing level of education
with three categories. Basic education meant compulsory education
with no vocational training beyond a vocational course or on the job
training, high meant a degree from higher vocational institutions,
polytechnics or universities, and secondary was between these cate-
gories, e.g. completion of vocational school. (Aromaa and Koskinen,
2004)
Current place of residence was categorized based on Statistics
Finland's classification as urban, semi-urban and rural. Region of re-
sidence was categorized based on the university hospital districts as
Northern, Eastern, Western, Southwestern, and Southern Finland.
2.4. Other variables
The participants were asked about cat ownership in a questionnaire,
categorized as current, previous and never. This variable was added in
the models, because domestic cats are a potential source of infection.
A previous Nordic study has found that T. gondii seropositivity is
associated with higher values of C-reactive protein (CRP) (Birgisdóttir
et al., 2006), which in turn is associated with both depression (Young
et al., 2014) and anxiety (Copeland et al., 2012). Therefore, we in-
vestigated whether associations between mental health and T. gondii
seropositivity changed after adjusting for CRP level. Serum high-sen-
sitivity CRP levels (mg/L) had been measured in the Health 2000 study
using automated analyser (Optima, Thermo Electron Oy, Vantaa, Fin-
land) and an immunoturbidimetric test (Ultrasensitive CRP, Orion Di-
agnostica, Espoo, Finland), as described in detail in Heikkilä et al.
(2011).
We controlled for the effect of antidepressant use, because one
previous study found suggestive evidence that they may be associated
with serointensity in patients with MDD (Hinze-Selch et al., 2007).
2.5. T. gondii IgG level measurement
Concentration of IgG antibodies to Toxoplasma gondii was mea-
sured by solid phase enzyme immunoassay employing whole tachyzoite
lysate from Ross South Labs, Spanish Fork Utah, USA employing
methods similar to those which have been previously described
(Dickerson et al., 2007). Sample values were converted to international
units by comparison to standards with known levels of antibody.
We used 50 IU/ml as the cut-off for seropositivity, as in Sugden et al.
(2016). In addition, serointensity, defined as the quantitative level of
Table 1
Descriptive information of the participants.
Variable N with available
data on the variable
Proportion (%) or mean
with 95% CI




































Antidepressant use 7112 5.8% (5.3–6.4%)
BDI-21 6311 7.1 (6.9–7.3)
C-reactive protein 6266 2.22 (2.08–2.37)
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antibody in IU/ml, was analyzed as a continuous variable.
2.6. Statistical analysis
Statistical analyses were conducted using the SUDAAN software,
Release 11.0.1, which takes the two-stage cluster sampling design into
account. In addition, post-stratification weights calibrated in Statistics
Finland were applied to adjust for non-response and for the over-
sampling of individuals aged 80 years and over.
We calculated the prevalence of toxoplasma seropositivity by so-
ciodemographic features, cat ownership and mental disorders, ad-
justing for age and sex. This was done using SUDAAN's RLOGIST pro-
cedure, calculating predictive margins using the PREDMARG
command. These predictive margins were adjusted for age and sex and
provide more comparable results than the crude prevalences (Bieler
et al., 2010). Similar analysis for serointensity was performed using
SUDAAN's REGRESS procedure.
We used logistic regression (SUDAAN's RLOGIST) to investigate the
association of T. gondii seropositivity with mental disorders, after ad-
justing for other variables associated with mental disorders or T. gondii
seroprevalence. Besides investigating the association of T. gondii ser-
opositivity with 12-month depressive, anxiety and alcohol use disorders
separately, we also investigated whether it was associated with co-
morbid depressive and anxiety disorders. Linear regression (SUDAAN's
REGRESS procedure) was used to investigate the association of T. gondii
seropositivity with current depressive symptoms after adjusting simi-
larly for other relevant variables. In regression models including CRP
levels, also the interaction between T. gondii seropositivity and CRP
level was tested. All statistical tests were two-tailed, and p< .05 was
used to define a significant difference.
3. Results
3.1. Toxoplasma seroprevalence and its association with sociodemographic
factors
The seroprevalence of T. gondii in the study population was 19.7%
(95% CI 18.3–21.2%) (Supplementary Table 1). Seroprevalences in men
and women in different age groups are reported in Supplementary
Table 2. The seroprevalence of T. gondii was highest in the southwestern
and lowest in the northern Finland, with no significant urban-rural
differences. Seroprevalence was higher in women than in men and in-
creased by age, with no significant differences by education or marital
status. People who currently had a cat had a higher seroprevalence rate
than those who had previously or never had a cat. (Supplementary
Table 1)
3.2. Toxoplasma seroprevalence and mental health
Adjusting for age and sex, T. gondii seroprevalence was not higher in
people with 12-month anxiety, depressive or alcohol use disorders, al-
though there was a suggestive association between seroprevalence and
anxiety disorders (P = 0.08) (Table 2). We further analyzed different
anxiety and depressive disorders separately. With the exception of
agoraphobia, the prevalence was higher in all diagnostic groups in
those who were T. gondii seropositive than in T. gondii seronegative, but
this was statistically significant only for GAD (Table 2). Separate ana-
lyses for men and women are reported in Tables 3 and 4 and revealed a
significantly higher prevalence of dysthymia in T. gondii seropositive
men and a significantly higher prevalence of GAD in T. gondii ser-
opositive women than in those who were seronegative.
People who were T. gondii seropositive had higher BDI-21 scores:
the age- and sex-adjusted mean score was 7.5 (95% CI 7.0–7.9) in those
who were seropositive and 6.9 (95% CI 6.7–7.1) in those who were
seronegative (P = 0.009). When this was analyzed separately for men
and women, women who were T. gondii seropositive had significantly
higher BDI scores (8.6 (95% CI 8.0–9.1)) than women who were ser-
onegative (7.6 (95% CI 7.3–7.9), P = 0.001), but in men there were no
significant differences between the groups (mean BDI in seropositives
Table 2
12-month prevalence of different anxiety and depressive disorders in participants who
were toxoplasma seropositive or seronegative; calculated as predictive margins adjusting





(% with 95% CI)a
Prevalence in T.
gondii seronegative




Panic disorder 2.4% (1.7–3.6%) 1.8% (1.4–2.3%) 0.17
Agoraphobia 0.5% (0.2–1.1%) 0.6% (0.4–0.8%) 0.88
GAD 1.9% (1.2–3.0%) 1.2% (0.9–1.5%) 0.04
Social phobia 1.5% (0.9–2.6%) 0.9% (0.7–1.2%) 0.09
Any anxiety
disorder
5.1% (3.8–6.6%) 3.8% (3.3–4.5%) 0.08
MDD 5.0% (3.8–6.6%) 4.8% (4.2–5.4%) 0.75
Dysthymia 2.8% (2.0–3.9%) 2.3% (1.9–2.8%) 0.33
Any depressive
disorder




2.5% (1.7–3.8%) 1.4% (1.1–1.7%) 0.01
Alcohol use
disorder
4.3% (3.1–6.0%) 4.5% (4.0–5.2%) 0.76
a Adjusted for age and sex.
Table 3
12-month prevalence of different anxiety and depressive disorders in men who were






(% with 95% CI)a
Prevalence in T.
gondii seronegative




Panic disorder 2.1% (1.0–4.2%) 1.3% (0.8–1.9%) 0.24
Agoraphobia 0.7% (0.2–2.1%) 0.5% (0.3–0.9%) 0.68
GAD 1.5% (0.7–3.2%) 1.2% (0.8–1.9%) 0.72
Social phobia 1.9% (0.9–2.9%) 1.0% (0.7–1.5%) 0.13
Any anxiety
disorder
4.3% (2.7–6.7%) 3.4% (2.7–4.2%) 0.39
MDD 3.8% (2.3–6.0%) 3.3% (2.6–4.2%) 0.64
Dysthymia 3.2% (1.9–5.3%) 1.6% (1.1–2.3%) 0.032
Any depressive
disorder
5.6% (3.7–8.2%) 4.3% (3.5–5.3%) 0.28
Alcohol use
disorder
6.8% (4.7–9.7%) 7.9% (6.8–9.1%) 0.44
a Adjusted for age.
Table 4
12-month prevalence of different anxiety and depressive disorders in women who were






(% with 95% CI)a
Prevalence in T.
gondii seronegative




Panic disorder 2.8% (1.8–4.4%) 2.3% (1.7–3.0%) 0.41
Agoraphobia 0.4% (0.1–1.2%) 0.6% (0.3–1.0%) 0.57
GAD 2.2% (1.4–3.6%) 1.1% (0.7–1.5%) 0.016
Social phobia 1.3% (0.6–2.6%) 0.9% (0.6–1.3%) 0.42
Any anxiety
disorder
5.7% (4.1–7.9%) 4.2% (3.5–5.2%) 0.14
MDD 6.3% (4.6–8.6%) 6.2% (5.3–7.2%) 0.91
Dysthymia 2.8% (1.8–4.2%) 3.0% (2.4–3.8%) 0.71
Any depressive
disorder
8.2% (6.3–10.6%) 8.2% (7.1–9.4%) 0.98
Alcohol use
disorder
1.9% (1.0–3.6%) 1.4% (1.0–2.0%) 0.42
a Adjusted for age.
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6.2 (95% CI 5.6–6.8) and in seronegatives 6.1 (95% CI 5.8–6.4), P =
0.73). Using the ≥ 14 cut-off for at least mild depressive symptoms,
17.5% (95% CI 15.3–20.0%) of T. gondii seropositive participants had at
least mild current depressive symptoms, compared to 14.5% (95% CI
13.5–15.5%) of T. gondii seronegative participants (P = 0.014). Of
note, people with 12-month anxiety disorder had similar BDI-21 scores
as those with 12-month depressive disorder: adjusting for age and sex,
the mean BDI-21 score was 17.4 (95% CI 16.1–18.8) in those with 12-
month anxiety disorder and 17.1 (95% CI 16.1–18.1) in those with 12-
month depressive disorder.
We investigated whether T. gondii seropositivity was a significant
predictor of 12-month anxiety or depressive disorders after adjusting
for factors known to increase the prevalence of anxiety disorders or T.
gondii seroprevalence: age, sex, region of residence, education, marital
status, cat ownership and other 12-month diagnoses. T. gondii ser-
opositivity was not a significant predictor in these logistic regression
models. Analogously, we investigated whether T. gondii seropositivity
was a significant predictor of BDI scores, adjusting for age, sex, region
of residence, education, marital status, cat ownership and 12-month
diagnoses. T. gondii seropositivity remained significantly associated
with higher BDI scores (beta 0.56, 95% CI 0.12–1.00, P = 0.013).
3.3. Effect of inflammation
Adjusted for age and sex, T. gondii seropositivity was associated with
higher CRP levels (2.6, 95% CI 2.2–2.9 vs. 2.1, 95% CI 2.0–2.3, P =
0.045). When CRP was added to the regression models, the results re-
garding T. gondii seropositivity did not change. CRP was a significant
predictor of 12-month anxiety disorders (OR 1.02, 95% CI 1.01–1.03, P
= 0.002) but not 12-month depressive disorders. T. gondii ser-
opositivity remained a significant predictor of BDI score (beta 0.55,
95% CI 0.11–0.99, P = 0.014) after adjusting for CRP, whereas CRP
was a significant predictor of higher BDI scores as well (beta 0.047,
95% CI 0.02–0.07, P< .001). Results from this model are presented in
Table 5.
3.4. Effect of current antidepressive use
As a sensitivity analysis, we investigated whether adjusting for
current antidepressive use changes the results. Antidepressive use was
not significantly associated with seropositivity (Supplementary
Table 1), and adjusting for it did not change the non-significant findings
related to 12-month disorders or the significant association of T. gondii
seropositivity with current depressive symptoms (P = 0.018).
3.5. Effect of having concurrent anxiety and depressive disorder
Of those with 12-month depressive disorder (n = 391), 24.6% (n =
96) also had an anxiety disorder, whereas 39.8% (n = 96) of those with
12-month anxiety disorder (n = 241) also had a depressive disorder. All
depressive and anxiety disorders were associated with higher ser-
oprevalence rates, although the effect was not significant for any in-
dividual disorder. Based on this and the significant association between
current depressive symptoms, we investigated whether T. gondii
seropositivity was associated with comorbid anxiety and depressive
disorder. We found that the prevalence of a comorbid depressive and
anxiety disorder was significantly higher (2.5%, 95% CI 1.7–3.8%) in
those who were T. gondii seropositive than in those who were ser-
onegative for T. gondii (1.4%, 95% CI 1.1–1.7%) (Table 2). Adjusting for
age, sex, region of residence, education, marital status and cat owner-
ship, T. gondii seropositivity was significantly associated with having
comorbid depressive and anxiety disorder (OR 1.73, 95% CI 1.02–2.92,
P = 0.042). Further adjustment for CRP did not affect the association of
comorbid depressive and anxiety disorder with T. gondii seropositivity
(OR 1.72, 95% CI 1.02–2.91, P = 0.043), while the effect of CRP was
also significant (OR 1.02, 95% CI 1.00–1.04, P = 0.015).
3.6. Toxoplasma serointensity
When the quantitative level of antibody was investigated instead of
dichotomous seropositivity, T. gondii serointensity remained a sig-
nificant predictor of BDI score (P = 0.017) after adjusting for age, sex,
region, education, cat ownership and 12-month mental disorders, and
remained significant (P = 0.019) also after CRP and antidepressive use
were added in the model. In contrast, the association of serointensity
with GAD or comorbid anxiety and depressive disorder did not reach
statistical significance in the full model. When this analysis was re-
stricted to T.gondii seropositive participants only, T. gondii serointensity
and CRP level both lost their statistical significance.
4. Discussion
Consistent with previous studies (Groër et al., 2011; Duffy et al.,
2015), T. gondii seropositivity and serointensity were associated with
current depressive symptoms. They were not associated with 12-month
depressive disorders with the exception of dysthymia in men. Lack of
association with MDD is consistent with the meta-analysis by Sutterland
et al. (2015) and with findings from the National Health and Nutrition
Survey (Pearce et al., 2012), although high serointensity has previously
been associated with MDD (Hinze-Selch et al., 2007). We found a sig-
nificant association between T. gondii seropositivity and GAD, which is
consistent with the study by Markovitz et al. (2015) but not with the
NHANES study (Gale et al., 2014). Furthermore, T. gondii seropositivity
predicted having both depressive and anxiety disorder concurrently.
The finding concerning comorbidity between depressive and anxiety
disorders is consistent with the recent study on mixed anxiety and de-
pressive disorders (9).
Although the association between T. gondii seropositivity and an-
xiety disorders was statistically significant only for GAD, the finding
was fairly similar for social phobia and panic disorder as well, sug-
gesting that T. gondii seropositivity is associated with anxiety.
Unfortunately, the Health 2000 Survey did not include a specific
measure of anxiety symptoms. However, the significant association
with current depressive symptoms and comorbid depressive and an-
xiety disorder also implies that T. gondii seropositivity and serointensity
are associated with more severe forms of depression and anxiety. This
would fit with previous associations of T. gondii seropositivity with
suicide attempts (Pedersen et al., 2012; Alvarado-Esquivel et al., 2013).
Table 5
Linear regression model of Beck Depression Inventory (BDI-21) score; adjusted for age, sex, education, region of residence, marital status and cat ownership.
Variablea Beta coefficient (95% confidence interval) Wald χ2 (degrees of freedom in parentheses) P value
Toxoplasma seropositive 0.55 (0.11–0.99) 6.00 (1) 0.014
12-month alcohol use disorder 3.65 (2.49–4.81) 37.9 (1) < .001
12-month depressive disorder 9.10 (8.04–10.11) 287.9 (1) < .001
12-month anxiety disorder 6.06 (4.77–7.35) 85.0 (1) < .001
CRP (mg/l) 0.047 (0.02–0.07) 12.3 (1) 0.001
a All variables (age, sex, education, region of residence, marital status, cat ownership, toxoplasma seropositivity, 12-month disorders and CRP) were entered simultaneously in the
model.
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Unfortunately, data on suicidal ideation and attempts were not sys-
tematically collected in the current study. Higher IgG levels may be
related to higher rate of exposure to T. gondii in people with current
depressive symptoms, but could also reflect a more recent infection, or
reactivation of a latent infection (Montoya, 2002).
Two previous studies have reported that T. gondii seropositivity is
associated with higher CRP level (Birgisdóttir et al., 2006; Hinze-Selch
et al., 2007), which has also been observed in a mouse model of chronic
T. gondii infection (Tomasik et al., 2016). Elevated CRP, in turn, may
predispose to depressive symptoms (Valkanova et al., 2013). Con-
sistently with previous research, CRP was associated both with T. gondii
seropositivity and with depressive symptoms and 12-month anxiety
disorders. However, adjusting for CRP level did not change the sig-
nificant association between T. gondii seropositivity and current de-
pressive symptoms, suggesting that the effect of T. gondii was not
mediated by inflammation. A recent study found an association be-
tween unipolar depression and cat scratches, but not with T. gondii
seropositivity, suggesting that another pathogen than T. gondii, possibly
the agent causing cat-scratch disease might explain the association
(Flegr and Hodný, 2016). In our analyses, we controlled for cat own-
ership but did not have information on cat scratches.
The seroprevalence of T. gondii in our study of individuals in Finland
was 19.7%. Globally, T. gondii seroprevalence is highest in warm and
humid climates and in populations with low socioeconomic status,
whereas seroprevalence rates found in Iceland and Norway, other
Nordic countries with long, snowy winters, are similar to our finding
(Pappas et al., 2009). The prevalence in eastern Finland, 18.0%, is
slightly higher than in a previous study which found 7.0% ser-
opositivity for T. gondii in eastern Finland using the complement fixa-
tion test (von Hertzen et al., 2006). In this study, the seroprevalence
was almost three times higher in geographically adjacent Russian
Karelia, showing the importance of environmental factors in addition to
climate on seroprevalence rates (von Hertzen et al., 2006). Consistently
with previous research, current cat ownership was a risk factor for T.
gondii seropositivity. About half of domestic cats in Finland are ser-
opositive for T. gondii, with no geographic variation in seroprevalence
rates (Jokelainen et al., 2012). Undercooked meat could be another
route of exposure; T. gondii has been found from moose, deer and do-
mestic sheep in Finland, with a clear geographical gradient in these
animals (Jokelainen et al., 2010).
The major strength of the study is that due to its sampling design,
the Health 2000 study sample is representative of the adult Finnish
population (Aromaa and Koskinen, 2004), and the participation rate
was excellent: 88.6% to the health interview or examination and 74.8%
to the CIDI interview. Sampling weights were used to adjust for sam-
pling variability and non-response. Therefore, the findings can be
generalized to the whole adult Finnish population.
5. Limitations
Despite having a large population-based study sample, the number
of participants with anxiety and depressive disorders was still limited,
and the lack of significant association of T. gondii with several anxiety
disorders despite higher point prevalence in seropositivity and higher
serointensity may reflect limited statistical power. Statistical power in
detecting significant differences in a continuous variable like BDI was
better. We did not use any correction for multiple comparisons. Finland
is a Nordic country with low T. gondii seroprevalence compared to most
other countries. The meta-analysis by Sutterland et al. (2015) found a
stronger association between T. gondii and mental disorders in Africa,
South America, Asia and the Middle East than in Europe or North
America, which could indicate strain-specific effects. Therefore, it is
possible that the reported associations would be stronger in countries
with higher seroprevalence rates. In addition, timing of the infection
was not known in the current study. This would be important in order
to understand whether the observed associations between T. gondii
seropositivity and depressive symptoms, GAD and comorbid anxiety
and depressive disorders were caused by a recent infection or by a re-
activation of a latent infection.
6. Conclusions
This study adds to the previous literature on the impact of T. gondii
infection on mental health. We found that people who were T. gondii
seropositive had more depressive symptoms, and T. gondii seropositivity
was also associated with comorbid depressive and anxiety disorders and
with GAD. While the most apparent contribution on the total disease
burden attributed to T. gondii globally arises from congenital tox-
oplasmosis and toxoplasmosis in immunocompromised host (Opsteegh
et al., 2015), there is growing evidence of its significance as a risk factor
for several mental disorders (Sutterland et al., 2015) as well as ag-
gression and impulsivity (Cook et al., 2015; Coccaro et al., 2016) and
other health problems (Flegr and Escudero, 2016).
According to a European multicentre case-control study in pregnant
women, the main sources of infection in European populations were
inadequately cooked or cured meat, contact with soil, working with
animals and travel outside Europe or United States and Canada (Cook
et al., 2000). Drinking unpasteurised milk or untreated water was also
important in some countries (Cook et al., 2000). Until an effective T.
gondii vaccine for cats is developed and implemented, prevention of T.
gondii infections needs to focus on reducing exposure to food-borne
infections and infections arising from contact to contaminated soil or
water through health education and decontamination of meat products
(Opsteegh et al., 2015). Since cats become infected mainly through
hunting and eating infected animals, keeping them indoors will lower
the rate of infection, and also prevents oocysts from infected cats
ending up in the environment (Opsteegh et al., 2015).
Consistent with previous studies, T. gondii seroprevalence and ser-
ointensity were associated with current depressive symptoms but not
with 12-month depressive disorders. These findings raise questions: is
this related to having a recent infection? Or is it possible that current
depressive symptoms trigger reactivation of a latent infection, reflected
as a higher antibody level? Yet another possibility is that T. gondii in-
fection is associated with more severe and persisting depressive
symptoms. Longitudinal studies on patients with depressive and anxiety
disorders are needed to further evaluate the role of T. gondii infection in
these disorders.
Financial disclosures
This study was funded by grant P50MH094268 from the NIMH (RH
Yolken) and by the Stanley Medical Research Institute (RH Yolken). The
authors report no biomedical financial interests or potential conflicts of
interest.
Role of the funding source
This study was funded by grant P50MH094268 from the NIMH (RH
Yolken) and by the Stanley Medical Research Institute (RH Yolken). The
funding sources had no role in the design or implementation of the
study, interpretation of the results, or preparation of the manuscript.
Acknowledgments
This study was funded by grant P50MH094268 from the NIMH (RH
Yolken) and by the Stanley Medical Research Institute (RH Yolken). The
funding sources had no role in the design or implementation of the
study, interpretation of the results, or preparation of the manuscript.
We thank Dr. Glen Ford, VanPelt Biosciences, Montgomery Village, MD,
USA, for carrying out the toxoplasma antibody measurements.
J. Suvisaari et al. Journal of Affective Disorders 223 (2017) 20–25
24
Appendix A. Supplementary material
Supplementary data associated with this article can be found in the
online version at http://dx.doi.org/10.1016/j.jad.2017.07.020.
References
Alvarado-Esquivel, C., Sánchez-Anguiano, L.F., Arnaud-Gil, C.A., López-Longoria, J.C.,
Molina-Espinoza, L.F., Estrada-Martínez, S., Liesenfeld, O., Hernández-Tinoco, J.,
Sifuentes-Álvarez, A., Salas-Martínez, C., 2013. Toxoplasma gondii infection and sui-
cide attempts: a case-control study in psychiatric outpatients. J. Nerv. Ment. Dis. 201,
948–952.
Alvarado-Esquivel, C., Sanchez-Anguiano, L.F., Hernandez-Tinoco, J., Berumen-Segovia,
L.O., Torres-Prieto, Y.E., Estrada-Martinez, S., Perez-Alamos, A.R., Ortiz-Jurado,
M.N., Molotla-de-Leon, G., Beristain Garcia, I., Rabago-Sanchez, E., Liesenfeld, O.,
2016. Toxoplasma gondii infection and mixed anxiety and depressive disorder: a case-
control seroprevalence study in Durango, Mexico. J. Clin. Med. Res. 8, 519–523.
Beck, A.T., Ward, C.H., Mendelson, M., Mock, J., Erbaugh, J., 1961. An inventory for
measuring depression. Arch. Gen. Psychiatry 4, 561–571.
Bieler, G.S., Brown, G.G., Williams, R.L., Brogan, D.J., 2010. Estimating model-adjusted
risks, risk differences, and risk ratios from complex survey data. Am. J. Epidemiol.
171, 618–623.
Birgisdóttir, A., Asbjörnsdottir, H., Cook, E., Gislason, D., Jansson, C., Olafsson, I.,
Gislason, T., Jogi, R., Thjodleifsson, B., 2006. Seroprevalence of Toxoplasma gondii in
Sweden, Estonia and Iceland. Scand. J. Infect. Dis. 38, 625–631.
Coccaro, E.F., Lee, R., Groër, M.W., Can, A., Coussons-Read, M., Postolache, T.T., 2016.
Toxoplasma gondii infection: relationship with aggression in psychiatric subjects. J.
Clin. Psychiatry 77, 334–341.
Cook, A.J., Gilbert, R.E., Buffolano, W., Zufferey, J., Petersen, E., Jenum, P.A., Foulon,
W., Semprini, A.E., Dunn, D.T., 2000. Sources of toxoplasma infection in pregnant
women: European multicentre case-control study. European Research Network on
Congenital Toxoplasmosis. Br. Med. J. 321, 142–147.
Cook, T.B., Brenner, L.A., Cloninger, C.R., Langenberg, P., Igbide, A., Giegling, I.,
Hartmann, A.M., Konte, B., Friedl, M., Brundin, L., Groer, M.W., Can, A., Rujescu, D.,
Postolache, T.T., 2015. "Latent" infection with Toxoplasma gondii: association with
trait aggression and impulsivity in healthy adults. J. Psychiatr. Res. 60, 87–94.
Copeland, W.E., Shanahan, L., Worthman, C., Angold, A., Costello, E.J., 2012.
Generalized anxiety and C-reactive protein levels: a prospective, longitudinal ana-
lysis. Psychol. Med. 42, 2641–2650.
Dickerson, F., Boronow, J., Stallings, C., Origoni, A., Yolken, R., 2007. Toxoplasma gondii
in individuals with schizophrenia: association with clinical and demographic factors
and with mortality. Schizophr. Bull. 33, 737–740.
Duffy, A.R., Beckie, T.M., Brenner, L.A., Beckstead, J.W., Seyfang, A., Postolache, T.T.,
Groer, M.W., 2015. Relationship between Toxoplasma gondii and mood disturbance in
women veterans. Mil. Med. 180, 621–625.
Flegr, J., Escudero, D.Q., 2016b. Impaired health status and increased incidence of dis-
eases in Toxoplasma-seropositive subjects – an explorative cross-sectional study.
Parasitology 143, 1974–1989.
Flegr, J., Hodný, Z., 2016a. Cat scratches, not bites, are associated with unipolar de-
pression – cross-sectional study. Parasit. Vectors 9, 8.
Gale, S.D., Brown, B.L., Berrett, A., Erickson, L.D., Hedges, D.W., 2014. Association be-
tween latent toxoplasmosis and major depression, generalised anxiety disorder and
panic disorder in human adults. Folia Parasitol. 61, 285–292.
Groër, M.W., Yolken, R.H., Xiao, J.C., Beckstead, J.W., Fuchs, D., Mohapatra, S.S.,
Seyfang, A., Postolache, T.T., 2011. Prenatal depression and anxiety in Toxoplasma
gondii-positive women. Am. J. Obstet. Gynecol. 204 (433), e1–e7.
Heikkilä, K., Silander, K., Salomaa, V., Jousilahti, P., Koskinen, S., Pukkala, E., Perola, M.,
2011. C-reactive protein-associated genetic variants and cancer risk: findings from
FINRISK 1992, FINRISK 1997 and Health 2000 studies. Eur. J. Cancer 47, 404–412.
von Hertzen, L.C., Laatikainen, T., Mäkelä, M.J., Jousilahti, P., Kosunen, T.U., Petäys, T.,
Pussinen, P.J., Haahtela, T., Vartiainen, E., 2006. Infectious burden as a determinant
of atopy – a comparison between adults in Finnish and Russian Karelia. Int. Arch.
Allergy Immunol. 140, 89–95.
Hinze-Selch, D., Däubener, W., Eggert, L., Erdag, S., Stoltenberg, R., Wilms, S., 2007. A
controlled prospective study of toxoplasma gondii infection in individuals with schi-
zophrenia: beyond seroprevalence. Schizophr. Bull. 2007 (33), 782–788.
In: Aromaa, A., Koskinen, S. (Eds.), 2004. Health and Functional Capacity in Finland.
Baseline Results of the Health 2000 Health Examination Survey. Publications of the
National Public Health Institute B12, 2004. Available in English at 〈http://www.
julkari.fi/handle/10024/78534〉. (Accessed 7 February 2017).
Jokelainen, P., Näreaho, A., Knaapi, S., Oksanen, A., Rikula, U., Sukura, A., 2010.
Toxoplasma gondii in wild cervids and sheep in Finland: north-south gradient in
seroprevalence. Vet. Parasitol. 171, 331–336.
Jokelainen, P., Simola, O., Rantanen, E., Näreaho, A., Lohi, H., Sukura, A., 2012. Feline
toxoplasmosis in Finland: cross-sectional epidemiological study and case series study.
J. Vet. Diagn. Investig. 24, 1115–1124.
Markovitz, A.A., Simanek, A.M., Yolken, R.H., Galea, S., Koenen, K.C., Chen, S., Aiello,
A.E., 2015. Toxoplasma gondii and anxiety disorders in a community-based sample.
Brain Behav. Immun. 43, 192–197.
Miman, O., Mutlu, E.A., Ozcan, O., Atambay, M., Karlidag, R., Unal, S., 2010. Is there any
role of Toxoplasma gondii in the etiology of obsessive-compulsive disorder? Psychiatry
Res. 177, 263–265.
Montoya, J.,G., 2002. Laboratory diagnosis of Toxoplasma gondii infection and tox-
oplasmosis. J. Infect. Dis. 185 (Suppl 1), S73–S82.
Montoya, J.G., Liesenfeld, O., 2004. Toxoplasmosis. Lancet 363, 1965–1976.
Opsteegh, M., Kortbeek, T.M., Havelaar, A.H., van der Giessen, J.W., 2015. Intervention
strategies to reduce human Toxoplasma gondii disease burden. Clin. Infect. Dis. 60,
101–107.
Pappas, G., Roussos, N., Falagas, M.E., 2009. Toxoplasmosis snapshots: global status of
Toxoplasma gondii seroprevalence and implications for pregnancy and congenital
toxoplasmosis. Int. J. Parasitol. 39, 1385–1394.
Pearce, B.D., Kruszon-Moran, D., Jones, J.L., 2012. The relationship between Toxoplasma
gondii infection and mood disorders in the third National Health and Nutrition
Survey. Biol. Psychiatry 72, 290–295.
Pedersen, M.G., Mortensen, P.B., Norgaard-Pedersen, B., Postolache, T.T., 2012.
Toxoplasma gondii infection and self-directed violence in mothers. Arch. Gen.
Psychiatry 69, 1123–1130.
Pirkola, S.P., Isometsä, E., Suvisaari, J., Aro, H., Joukamaa, M., Poikolainen, K., Koskinen,
S., Aromaa, A., Lönnqvist, J.K., 2005. DSM-IV mood-, anxiety- and alcohol use dis-
orders and their comorbidity in the Finnish general population – results from the
Health 2000 Study. Soc. Psychiatry Psychiatr. Epidemiol. 40, 1–10.
Saadatnia, G., Golkar, M., 2012. A review on human toxoplasmosis. Scand. J. Infect. Dis.
44, 805–814.
Sugden, K., Moffitt, T.E., Pinto, L., Poulton, R., Williams, B.S., Caspi, A., 2016. Is
Toxoplasma gondii infection related to brain and behavior impairments in humans?
Evidence from a population-representative birth cohort. PLoS One 11, e0148435.
Sutterland, A.L., Fond, G., Kuin, A., Koeter, M.W., Lutter, R., van Gool, T., Yolken, R.,
Szoke, A., Leboyer, M., de Haan, L., 2015. Beyond the association. Toxoplasma gondii
in schizophrenia, bipolar disorder, and addiction: systematic review and meta-ana-
lysis. Acta Psychiatr. Scand. 132, 161–179.
Tomasik, J., Schultz, T.L., Kluge, W., Yolken, R.H., Bahn, S., Carruthers, V.B., 2016.
Shared immune and repair markers during experimental toxoplasma chronic brain
infection and schizophrenia. Schizophr. Bull. 42, 386–395.
Valkanova, V., Ebmeier, K.P., Allan, C.L., 2013. CRP, IL-6 and depression: a systematic
review and meta-analysis of longitudinal studies. J. Affect. Disord. 150, 736–744.
Wittchen, H.U., Lachner, G., Wunderlich, U., Pfister, H., 1998. Test-retest reliability of the
computerized DSM-IV version of the Munich-Composite International Diagnostic
Interview (M-CIDI). Soc. Psychiatry Psychiatr. Epidemiol. 33, 568–578.
Young, J.J., Bruno, D., Pomara, N., 2014. A review of the relationship between proin-
flammatory cytokines and major depressive disorder. J. Affect. Disord. 169, 15–20.
Zhang, Y., Träskman-Bendz, L., Janelidze, S., Langenberg, P., Saleh, A., Constantine, N.,
Okusaga, O., Bay-Richter, C., Brundin, L., Postolache, T.T., 2012. Toxoplasma gondii
immunoglobulin G antibodies and nonfatal suicidal self-directed violence. J. Clin.
Psychiatry 73, 1069–1076.
Jaana Suvisaari, M.D., Ph.D., is a psychiatrist working as a
research professor and the head of Mental Health Unit at
the National Institute for Health and Welfare, Helsinki,
Finland. Her main research interests are the epidemiology
and genetic and environmental risk factors of major psy-
chiatric disorders, with over 200 international peer-re-
viewed articles.
J. Suvisaari et al. Journal of Affective Disorders 223 (2017) 20–25
25
